Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

Other analysts also recently issued reports about the stock. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Scotiabank assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 13th. They issued a “sector perform” rating and a $650.00 price objective on the stock. Bank of America boosted their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday, October 29th. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Finally, Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $772.76.

Regeneron Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ REGN opened at $725.34 on Monday. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $800.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The firm’s 50 day simple moving average is $605.06 and its two-hundred day simple moving average is $572.50. The stock has a market capitalization of $76.23 billion, a P/E ratio of 17.37, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the business posted $12.46 EPS. The business’s quarterly revenue was up .9% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in REGN. Integrated Investment Consultants LLC boosted its stake in shares of Regeneron Pharmaceuticals by 10.5% during the 3rd quarter. Integrated Investment Consultants LLC now owns 756 shares of the biopharmaceutical company’s stock valued at $425,000 after purchasing an additional 72 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 22.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 287,881 shares of the biopharmaceutical company’s stock worth $161,867,000 after buying an additional 53,614 shares during the period. Morningstar Investment Management LLC boosted its position in Regeneron Pharmaceuticals by 238.1% during the 3rd quarter. Morningstar Investment Management LLC now owns 3,918 shares of the biopharmaceutical company’s stock valued at $2,203,000 after acquiring an additional 2,759 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 108.0% during the 3rd quarter. NewEdge Advisors LLC now owns 4,032 shares of the biopharmaceutical company’s stock worth $2,267,000 after acquiring an additional 2,094 shares during the period. Finally, Armistice Capital LLC grew its holdings in shares of Regeneron Pharmaceuticals by 25.2% during the 3rd quarter. Armistice Capital LLC now owns 125,206 shares of the biopharmaceutical company’s stock worth $70,400,000 after acquiring an additional 25,174 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.